Form Bio Launches AI-Powered FormManufacturing Platform to Address CGT Manufacturing Bottlenecks
核心洞察
Form Bio (搜索) announced the launch of FormManufacturing, an end-to-end AI-driven platform for predicting, optimizing, and monitoring manufacturability of cell and gene therapies from construct design through commercial scale-up.
The platform combines AI-driven design optimization (FormSightAI) with genomic quality analytics (FormBatchQC) to address manufacturing issues that trigger 74% of FDA rejections.
Across customer programs, Form Bio (搜索) has demonstrated an 8x improvement in genome integrity, 2-3x increase in manufacturing yield, and 5x improvement in controllable expression.
Form Bio (搜索), a leader in AI-powered genetic medicine development and genome engineering, today announced the launch of FormManufacturing, a new platform designed to predict, optimize, and monitor manufacturability for cell and gene therapies (CGT), from initial construct design through commercial scale-up. Debuting with an AAV (搜索)-focused offering, the platform integrates AI-driven design optimization with deep genomic characterization to address one of the industry's most critical challenges: ensuring that the therapy designed is the therapy consistently manufactured.
The Manufacturing Bottleneck in CGT
Manufacturing remains the primary bottleneck in cell and gene therapy development. According to Form Bio (搜索), 74% of FDA rejections are triggered by quality or manufacturing issues. Subtle genomic changes during cell line expansion, viral integration, and scale-up can alter product potency and safety, often without detection until late-stage development or regulatory review. At the same time, regulators increasingly expect quantitative, data-driven evidence of lot-to-lot comparability to support IND and BLA submissions.
FormManufacturing addresses this gap upstream by enabling developers to design for manufacturability from day one and track product integrity through scale-up.
Platform Capabilities: AI-Driven Design and Genomic Analytics
The FormManufacturing platform combines two core capabilities. The first, FormSightAI, screens thousands of constructs in silico to identify manufacturing risks—such as partial capsids, host contaminants, and CpG islands—before they reach the laboratory. The second, FormBatchQC, quantifies genome integrity, detects impurities, and provides defensible regulatory evidence of lot-to-lot consistency from tech transfer to commercialization.
"At Form Bio (搜索), we're redefining how biopharma developers ensure quality and reduce risk across the development and manufacturing lifecycle of genetic medicine," said Michelle Chen, Ph.D., President and CEO at Form Bio. "By combining payload characterization, AI-driven design optimization, and manufacturing comparability analytics, we deliver the molecular intelligence needed to scale high-quality CGT therapies from discovery through commercial manufacturing."
Demonstrated Performance Across Customer Programs
Across customer programs, Form Bio (搜索) has reported significant performance improvements: an 8x improvement in genome integrity, a 2-3x increase in manufacturing yield, and a 5x improvement in controllable expression.
Behzad Mahdavi, Ph.D., MBA, Founder of Innov2Gro and former senior executive at Lonza, Catalent, and Ginkgo Bioworks, commented on the broader industry context: "Traditional process improvements have reached their limits. The next frontier is biological optimization, designing therapeutics for manufacturability from day one. This is how we unlock scalable production, improve product quality, and accelerate time to market. Form Bio (搜索) brings the molecular and computational rigor needed to make that vision a reality."
ASGCT 2026 Scientific Presentations
Form Bio (搜索) will showcase FormManufacturing at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11–15 in Boston. Attendees can visit Booth #732 to learn more about the AI-powered approach to design and manufacturing. The company will also present scientific data through several high-profile collaborations, including:
- A scientific poster with UT Southwestern titled "Meta-Analysis of Genome Packaging and Vector Design of rAAV Vectors," scheduled for May 12 (Poster #1012).
- A scientific poster titled "Impact of Production Platform on AAV Capsid Composition, Purity, and Genome Integrity," scheduled for May 13 (Poster #2202).
- A scientific talk titled "Genomic Characterization of AAV Full Capsid Standards Across Multiple Serotypes and Two Distinct Production Platforms Using Multiplex dPCR and Long-Read Sequencing," scheduled for May 14 at 8:30 AM in Room 206AB.
About Form Bio (搜索)
Form Bio (搜索) is a leader in developing AI-powered solutions for genetic medicine and genome engineering. Since spinning out from Colossal Biosciences in 2022, the company has become a trusted innovation partner to cell and gene therapy developers. Form Bio's advanced in silico technology and computational platforms deliver deep insights into genome integrity, optimized payload design, and other critical factors—enabling safer, more efficacious, and more manufacturable therapeutics. By reducing risk, shortening timelines, and optimizing outcomes, Form Bio helps drug developers accelerate the path from discovery to the clinic.